**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 85146

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Plasma exosomal hsa\_circ\_0079439 as a novel biomarker for early detection of gastric cancer**

Li X *et al*. Exosomal hsa\_circ\_0079439 as a novel GC biomarker

Xiao Li, Yan-Li Lin, Jia-Kang Shao, Xiao-Jie Wu, Xiang Li, He Yao, Fa-Liang Shi, Long-Song Li, Wen-Gang Zhang, Zheng-Yao Chang, Ning-Li Chai, You-Liang Wang, En-Qiang Linghu

**Xiao Li, Long-Song Li, Wen-Gang Zhang, Ning-Li Chai, En-Qiang Linghu,** Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China

**Xiao Li, Jia-Kang Shao, Long-Song Li, Wen-Gang Zhang, Zheng-Yao Chang,** Medical School of Chinese PLA, Beijing 100853, China

**Xiao Li, Yan-Li Lin, Xiao-Jie Wu, Xiang Li, He Yao, Fa-Liang Shi, You-Liang Wang,** Beijing Institute of Biotechnology, Beijing 100071, China

**Author contributions:** ChaiNL, Wang YL, and Linghu EQ designed the study; Li X, Shao JK, Li LS, Zhang WG, and Chang ZY collected the plasma samples; Li X, Lin YL, Wu XJ, Yao H, Shi FL, and Li X performed the dd-PCR test and data analysis; Li X, Lin YL, and Shao JK contributed equally to this work, and they should be considered as co-first authors; ChaiNL, Wang YL, and Linghu EQ were co-corresponding authors; and all authors approved the final manuscript.

**Supported by** the National Key Research and Development Program, No. 2019YFA0903802, 2022YFC2503600, and 2016YFC1303601.

**Corresponding author: En-Qiang Linghu, PhD, Chief Physician, Professor,** Department of Gastroenterology, The First Medical Center of Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China. linghuenqiang@vip.sina.com

**Received:** April 16, 2023

**Revised:** May 4, 2023

**Accepted:** May 11, 2023

**Published online:**

**Abstract**

BACKGROUND

Due to the poor prognosis of gastric cancer (GC), early detection methods are urgently needed. Plasma exosomal circular RNAs (circRNAs) have been suggested as novel biomarkers for GC.

AIM

To identify a novel biomarker for early detection of GC.

METHODS

Healthy donors (HDs) and GC patients diagnosed by pathology were recruited. Nine GC patients and three HDs were selected for exosomal whole-transcriptome RNA sequencing. The expression profiles of circRNAs were analyzed by bioinformatics methods and validated by droplet digital polymerase chain reaction. The expression levels and area under receiver operating characteristic curve values of plasma exosomal circRNAs and standard serum biomarkers were used to compare their diagnostic efficiency.

RESULTS

There were 303 participants, including 240 GC patients and 63 HDs, involved in the study. The expression levels of exosomal hsa\_circ\_0079439 were significantly higher in GC patients than in HDs (*P* < 0.0001). However, the levels of standard serum biomarkers were similar between the two groups. The area under the curve value of exosomal hsa\_circ\_0079439 was higher than those of standard biomarkers, including carcinoembryonic antigen, carbohydrate antigen (CA)19-9, CA72-4, alpha-fetoprotein, and CA125 (0.8595 *vs* 0.5862, 0.5660, 0.5360, 0.5082, and 0.5018, respectively). The expression levels of exosomal hsa\_circ\_0079439 were significantly decreased after treatment (*P* < 0.05). Moreover, the expression levels of exosomal hsa\_circ\_0079439 were obviously higher in early GC (EGC) patients than in HDs (*P* < 0.0001).

CONCLUSION

Our results suggest that plasma exosomal hsa\_circ\_0079439 is upregulated in GC patients. Moreover, the levels of exosomal hsa\_circ\_0079439 could distinguish EGC and advanced GC patients from HDs. Therefore, plasma exosomal hsa\_circ\_0079439 might be a potential biomarker for the diagnosis of GC during both the early and late stages.

**Key Words:** Gastric cancer; Exosomes; Circular RNA; Droplet digital polymerase chain reaction; Biomarker

Li X, Lin YL, Shao JK, Wu XJ, Li X, Yao H, Shi FL, Li LS, Zhang WG, Chang ZY, Chai NL, Wang YL, Linghu EQ. Plasma exosomal hsa\_circ\_0079439 as a novel biomarker for early detection of gastric cancer. *World J Gastroenterol* 2023; In press

**Core Tip:** Gastric cancer (GC) remains a prevalent disease worldwide. Due to its atypical clinical manifestations, GC is usually diagnosed at late stages in most patients and has a poor prognosis. Therefore, early detection of GC is of great importance. Based on the results of exosomal whole-transcriptome RNA sequencing, we performed bioinformatic analysis and droplet digital polymerase chain reaction (dd-PCR) tests. As validated by dd-PCR, exosomal hsa\_circ\_0079439 had a higher area under the curve value than standard biomarkers. Therefore, plasma exosomal hsa\_circ\_0079439 could serve as a novel biomarker for the early detection of GC.

**INTRODUCTION**

Gastric cancer (GC) is the fifth most commonly diagnosed cancer and the fourth leading cause of cancer-related death; it accounted for 1089103 new cases and 768793 deaths in 2020 globally[1]. The prognosis of advanced GC (AGC) patients is poor[2]. Early detection of GC and identification of individuals who might benefit from a given treatment are of great importance. Unfortunately, the most common symptoms associated with GC are nonspecific, such as weight loss, poor appetite, and abdominal pain[2]. Based on the abovementioned conditions, the diagnosis of GC is often at a late stage[2]. Therefore, accurate early detection of GC is one of the most urgent issues in its management.

A previous study showed that carcinoembryonic antigen (CEA), carbohydrate antigen (CA)19-9, and CA72-4 levels are significantly associated with tumor stage and patient survival[3]. In addition, some studies have shown that CA125 and alpha-fetoprotein (AFP) are linked to GC[4,5]. However, the widespread use of less invasive detection methods has resulted in a number of inaccurate diagnoses due to their low sensitivity and specificity[6-8]. Therefore, it is necessary to identify novel biomarkers with higher accuracy for the early detection of GC.

Exosomes, a subset of nanometer-sized (50-150 nm) extracellular vesicles, can be secreted by almost all kinds of cells[9,10]. In addition, exosomes comprise diverse components, including proteins, DNAs, circular RNAs (circRNAs), long noncoding RNAs (lncRNAs), microRNAs (miRNAs), messenger RNAs (mRNAs), and lipids[10-13]. An increasing number of studies have shown that exosomes are involved in mediating intercellular communication and many pathological processes[9,10,14]. Therefore, they have great potential to become novel biomarkers in liquid biopsy. CircRNAs, a class of lncRNAs, were first discovered by electron microscopy more than 40 years ago[15-17]. Because of the exosomal phospholipid bilayer membrane structure, circRNAs are stable within exosomes.

Furthermore, a number of studies have demonstrated that circRNAs play an important role in GC progression, invasion, and metastasis. However, the utility of exosomal circRNAs for early detection of GC is largely unknown. Profiling circRNAs in exosomes could be useful for identifying molecular markers for early detection and prognosis prediction for various types of cancers[14,18-20].

In this study, we analyzed the expression levels of plasma exosomal circRNAs from GC patients in different clinical stages. The findings of this study support the notion that plasma exosomal circRNAs could serve as biomarkers for the diagnosis of early GC (EGC). Moreover, they might be considered as new therapeutic targets as well as effective prognostic markers for GC.

**MATERIALS AND METHODS**

***Definitions***

EGC is defined as GC confined to the mucosal and submucosal layers. Locally AGC (LAGC) was defined as stages T2-4aN0-3M0 GC, corresponding to stages Ib to IIIc and excluding T1 or T4b tumors[21-23]. Metastatic GC (MGC) refers to the invasion of GC cells into other tissues or organs. AGC includes LAGC and MGC[24].

***Patients and plasma sample collection***

A total of 240 GC patients (including 177 EGC patients and 63 AGC patients) and 63 healthy donors (HDs) were enrolled in our study from April 2018 to October 2022 (Figure 1). All of the GC patients had been diagnosed with adenocarcinoma after surgery. Patients who had been treated by chemoradiotherapy, targeted therapy, or cytotoxic therapy were excluded. HDs had undergone gastric endoscopy, and they did not have GC or any other gastric disease. We selected plasma exosomal samples obtained from nine GC patients (3 EGC, 3 LAGC, and 3 MGC) and three HDs for whole transcriptome RNA sequencing (nine GC patients were included in the validation cohort, and the expression levels of circRNA were verified). None of these GC patients had received any previous treatment before their first blood samples were obtained.

All participants were divided into a test cohort and a validation cohort. There were 69 GC patients and 22 HDs in the test cohort from April 2018 to December 2018. Another 171 GC patients and 41 HDs were included in the validation cohort from January 2019 to October 2022. According to the American Joint Committee on Cancer 8th edition[22,23], the clinical stage and TNM classification of GC in all patients were assessed and analyzed. All patients underwent endoscopic submucosal dissection or minimally invasive surgery to remove the lesions, which meant that accurate pathology results could be confirmed. In addition, plasma samples were acquired from GC patients 7 d after treatment.

Blood samples were collected from GC patients or HDs in K2-EDTA Blood Collection Tubes (Becton, Dickinson and Company). Blood samples were centrifuged at 500 × *g* for 15 min, and the supernatant collected was plasma. Plasma was transferred to a new tube and a unique classification number was written on the tube, which was then stored at -80 °C.

***Cell culture***

GC cells (GCCs) (AGS and HGC-27) were obtained from Shanghai Gaining Biological Technology Company (http://www.shgnsw.com). KATO III was obtained from the American Type Culture Collection (ATCC, http://www.atcc.org). Other GCCs (SNU-1, SGC-7901, MGC-803, and BGC-823) were obtained from the BeNa Culture Collection (BNCC, http://www.bncc.org.cn). Normal gastric epithelial cells (NGECs) were obtained from the Shanghai Qincheng Biological Technology Company (http://www.shqcsw.com). The culture methods used for the cell lines are shown in Supplementary Table 1.

***Isolation and purification of exosomes***

For whole-transcriptome RNA sequencing, exosomes were isolated by size-exclusion chromatography. We used a procedure described in a previous study with a few minor modifications[25]. PBS was used to perform a 1.5-fold dilution of 1 mL of each plasma sample (0.8 μm filtered). Then, the mixture was purified using Exosupur® columns (Echobiotech, China) and more PBS was used to perform elution, which resulted in a total of 2 mL of eluate. Finally, by using 100 kDa molecular weight cutoff Amicon® Ultra spin filters (Merck, Germany), the fractions obtained during the previous step were concentrated to 200 μL.

For droplet digital polymerase chain reaction (dd-PCR) test, plasma exosomes were isolated according to the manufacturer’s instructions for the ExoQuickTM Exosome Precipitation Solution (SBI). Briefly, 16 μL of thrombin was added to 1000 μL of plasma at a final concentration of 5 U/mL. The mixture was incubated at room temperature for 5 min and centrifuged at 10000 rpm for 5 min, and a visible pellet was observed at the bottom of the tube. The supernatant was transferred to a new tube and centrifuged at 3000 × *g* for 5 min to remove cells and other debris. The supernatant was transferred to a new tube; 63 μL of ExoQuick Exosome Precipitation Solution was added, and the mixture was incubated at 4 °C for 30 min. After centrifuging the mixture at 1500 × *g* for 30 min, the fluid was removed. The pellet at the bottom of the tube, which contained exosomes, was collected.

***Transmission electron microscopy***

Exosomes isolated from plasma were diluted. Ten microliters of exosome solution was added to a copper mesh and incubated for 10 min. After cleaning the mesh with sterile distilled water, filter paper was used to absorb the liquid. Ten microliters of 2% phosphotungstic acid was added to the copper mesh and incubated for 1 min. Then, the copper mesh was dried with filter paper. The copper mesh was kept dry for several minutes at room temperature. And transmission electron microscopy (TEM) was performed.

***Nanoparticle tracking analysis***

After the instrument qualification test, the diameter and quantity of the exosomes isolated from plasma were measured by ZetaView PMX 110 (Particle Metrix, Meerbusch). The movement of particles was analyzed by nanoparticle tracking analysis (NTA) software (ZetaView 8.02.28) by taking 60 s of video at a rate of 30 frames/s.

***Western blot analysis***

After total protein extraction from exosomes, the protein concentration was measured with the Pierce BCA Protein Assay kit (Thermo). Western blot (WB) analysis was performed to measure protein expression in the extracts. The positive markers of exosomes that were used included CD9 (Abcam), TSG101 (Abcam), and CD81 (Abcam). The negative marker was calnexin (Abcam).

***Total RNA extraction of exosomes and RNA analysis***

Total RNA was extracted from plasma exosomes and purified with the miRNeasy Serum/Plasma Advanced Kit (Qiagen). The concentration and purity were evaluated with the RNA Nano 6000 Assay Kit and an Agilent Bioanalyzer 2100 System (Agilent Technologies).

***Whole-transcriptome RNA library preparation and sequencing***

According to the instructions of the SMARTer Stranded Total RNA-Seq Kit V2 (Takara), a total amount of 250 pg-10 ng RNA per sample was used as input material for RNA-seq library preparation. For small RNA libraries, a total amount of 1 ng-500 ng RNA per sample was used as input material for the QIAseq miRNA Library Kit (Qiagen). The quality of RNA-seq libraries and small RNA libraries was assessed with an Agilent Bioanalyzer 2100 (Agilent Technologies). Based on the acBot Cluster Generation System, the index-coded samples were clustered using TruSeq PE Cluster Kitv3-cBot-HS (Illumina). Then, the prepared libraries were sequenced on an Illumina NovaSeq 6000 platform. Paired-end reads were generated at EchoBiotech Co. Ltd., Beijing, P. R. China.

***Bioinformatics analysis***

The R package DESeq2 was used for the differential expression analysis of circRNAs, lncRNAs, miRNAs, and mRNAs between HDs and GC patients. The criteria were set as |log2FC| > 1 and *P* < 0.01. The R package pheatmap was used for clustering analysis of these differentially expressed circRNAs, lncRNAs, miRNAs, and mRNAs. The Cancer-Specific CircRNA Database (CSCD) and CircInteractome databases were used to predict the target miRNAs of circRNAs. The TargetScan, miRDB, and miRTarBase databases were used to predict the target genes of miRNAs. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis and Gene Ontology (GO) functional enrichment analysis were performed with R 4.1.1 software to identify the enriched genes.

***Verification of circRNA expression by dd-PCR***

Dd-PCR was performed on a QX200 Droplet System using dd-PCR EvaGreen Supermix (Bio-Rad). The divergent primers overlapping the splice junction of hsa\_circ\_0079439 were designed by Primer-BLAST (Supplementary Table 2).

***Statistical analysis***

Statistical analyses were performed with SPSS 26.0 and GraphPad Prism 8.0. The expression levels of plasma exosomal hsa\_circ\_0079439 and standard serum biomarkers, including CEA, CA19-9, CA72-4, AFP, and CA125, were compared between the test cohort and validation cohort, and the differences were analyzed by the *t* test. The data are shown as the mean (SD). The expression levels and area under the receiver operating characteristic (ROC) curve (AUC) values of plasma exosomal hsa\_circ\_0079439 and standard serum biomarkers were used to assess their diagnostic efficiency for GC, EGC, and AGC. The results with *P* < 0.05 were considered significant.

**RESULTS**

***Clinical characteristics of patients***

There were 303 participants, including 63 HDs and 240 GC patients, enrolled in our study (Table 1). There were 177 patients (73.75%) with GC at T1 stage, 7 (2.92%) with GC at T2 stage, 37 (15.42%) with GC at T3 stage, and 19 (7.91%) with GC at T4 stage. Among these GC patients, 47 (19.58%) had lymph node metastasis, and 9 (3.75%) had distant metastasis. Most GC cases were in stage I (180, 75.00%), and others were in stage II (16, 6.67%), stage III (35, 14.58%), and stage IV (9, 3.75%). The median age (range) of the HD group was 53 years (24-81 years) and that of the GC group was 64 years (34-94 years). The ratio of males to females was 43/20 in the HD group, and 187/53 in the GC group.

***Isolation and identification of exosomes***

To characterize exosomes and confirm their isolation from GC patients and HDs, TEM, NTA, and WB analysis were performed. The exosomes appeared to be almost round in shape according to electron microscopy images (Figure 2A). NTA indicated that the diameter of exosomes ranged from 40 nm to 200 nm, which was consistent with previous research results[26] (Figure 2B). WB results showed that exosomes expressed typical markers, including CD9, TSG101, and CD81. The negative marker calnexin was not expressed (Figure 2C).

***Bioinformatic analysis of whole-transcriptome RNA sequencing results***

There were 14976 circRNAs, 3061 lncRNAs, 1629 miRNAs, and 12830 mRNAs identified by whole transcriptome RNA sequencing of exosomes. Clustering analysis was performed to reveal the differentially expressed circRNAs, lncRNAs, miRNAs, and mRNAs between HDs and GC patients. Unlike the relatively ambiguous clusters observed for the latter three RNA types (Supplementary Figures 1A-C), circRNAs were clearly clustered into five groups (Figure 2D). Based on data obtained from CSCD and CircInteractome, 2262 miRNA response elements were predicted. By intersecting the results obtained from TargetScan, miRDB, and miRTarBase, 8145 common potential target genes were identified. Then, we performed differential expression analyses of GC patient samples *vs* HD samples by using The Cancer Genome Atlas (TCGA) and identified 2512 genes (1072 upregulated, 1440 downregulated); 998 of these genes were also identified as potential targets in the abovementioned analysis. KEGG pathway analysis demonstrated that these genes were enriched in pathways in cancer, the cell cycle, and the PI3K-Akt signaling pathway (Supplementary Figure 2A). GO enrichment analysis indicated that these genes were associated with nuclear division, organelle fission, and cell cycle G1/S phase transition (Supplementary Figure 2B).

To further investigate the function of cluster 5 (68 circRNAs, marked in Figure 2D), similar analysis methods were used. These circRNAs were significantly upregulated in all GC samples, and 1731 target miRNAs were predicted. To identify potential miRNAs related to GC, we performed differential expression analyses based on TCGA and identified 64 miRNAs that were downregulated in GC samples *vs* HD samples. Thirty-one miRNAs were selected by taking the intersection of the two groups of results. These miRNAs were predicted to bind 1578 target genes. KEGG pathway analysis demonstrated that these genes were enriched in five pathways, including pathways in cancer, the PI3K-Akt signaling pathway, the MAPK signaling pathway, miRNAs in cancer, and cellular senescence (Figure 2E). GO enrichment analysis indicated that these genes were associated with nuclear division, organelle fission and cell cycle G1/S phase transition (Figure 2F).

We generated a circRNA-miRNA-mRNA regulatory network related to the genes enriched in the top 5 KEGG pathways. Ultimately, we found that six circRNAs (hsa\_circ\_0113953, hsa\_circ\_0076179, hsa\_circ\_0007353, hsa\_circ\_0012823, hsa\_circ\_0001470, and hsa\_circ\_0079439) were included in all the networks (Supplementary Figures 3A-E).

Similar to a previous study, the expression levels of ncRNAs in exosomes were consistent with those in GCCs or tissues[27]. Then, we assessed the expression levels of the six circRNAs in NGECs and GCCs (AGS, MGC-803, SGC-7901, HGC-27, SNU-1, KATO III, and BGC-823) (Supplementary Figures 4A-F). The results showed that the expression levels of hsa\_circ\_0079439 in the GCCs were obviously higher than those in NGECs. Thus, hsa\_circ\_0079439 was selected for further validation by dd-PCR. The primers used to measure the levels of the six circRNAs are shown in Supplementary Table 1.

***Expression levels of exosomal hsa\_circ\_0079439 in test and validation cohorts***

In the test cohort, the expression levels of exosomal hsa\_circ\_0079439 were significantly higher in GC patients than in HDs (*P* < 0.0001) (Figure 3A). In addition, the levels of serum CEA in GC patients were higher than those in HDs (*P* < 0.001) (Figure 3B). However, the expression levels of CA19-9, CA72-4, AFP, and CA125 were not significantly different between GC patients and HDs (Figures 3C-F).

Furthermore, in the validation cohort, we again found that the expression levels of exosomal hsa\_circ\_0079439 were significantly higher in GC patients than in HDs (*P* < 0.0001) (Figure 4A). However, the expression levels of standard serum biomarkers between GC patients and HDs were not significantly different (Figures 4B-F).

***Expression of exosomal hsa\_circ\_0079439 and its value in diagnosing GC, EGC, and AGC***

To evaluate the diagnostic value of exosomal hsa\_circ\_0079439 for GC, EGC, and AGC, we combined the data obtained from the test cohort and validation cohort. We compared the expression levels and analyzed the ROC curves of exosomal hsa\_circ\_0079439, CEA, CA19-9, CA72-4, AFP, and CA125. The expression levels of exosomal hsa\_circ\_0079439 were significantly higher in GC patients than in HDs (*P* < 0.0001) (Figure 5A). However, the levels of standard serum biomarkers showed no significant difference between GC patients and HDs (Figures 5B-F). The AUC value of exosomal hsa\_circ\_0079439 was higher than those of CEA, CA19-9, CA72-4, AFP, and CA125 (0.8595 *vs* 0.5862, 0.5660, 0.5360, 0.5082, and 0.5018, respectively) (Figure 5G). To investigate the changes in the expression levels of exosomal hsa\_circ\_0079439 before and after treatment, we analyzed 30 paired plasma samples obtained from GC patients. The expression levels of exosomal hsa\_circ\_0079439 were significantly decreased after treatment (Figure 5H) (*P* < 0.05).

To determine whether the results were similar in EGC patients, all GC patients were divided into two groups (EGC patients and AGC patients). The expression levels of exosomal hsa\_circ\_0079439 were obviously higher in EGC patients (*P* < 0.0001) and AGC patients (*P* < 0.0001) than in HDs (Figure 6A). However, the serum levels of CEA, CA19-9, CA72-4, AFP, and CA125 could not be used to distinguish EGC patients from HDs (Figures 6B-F). The AUC value of exosomal hsa\_circ\_0079439 was obviously higher than those of CEA, CA19-9, CA72-4, AFP, and CA125 (0.8433 *vs* 0.5732, 0.5362, 0.5203, 0.5024, and 0.5352, respectively) (Figure 6G).

In addition, the serum levels of CEA, CA19-9, and CA125 were apparently higher in AGC patients than in HDs (*P* < 0.05) (Figures 6B, C, and F). However, when comparing the levels of CA72-4 and AFP, there was no significant difference between AGC patients and HDs (Figures 6D and E). The AUC value of exosomal hsa\_circ\_0079439 was obviously higher than those of CEA, CA19-9, CA72-4, AFP, and CA125 (0.9050 *vs* 0.6228, 0.6497, 0.5801, 0.5379, and 0.6058, respectively) (Figure 6H).

**DISCUSSION**

Although the incidence and mortality rates of GC have declined over the past century, GC is still a major health problem worldwide, especially in East Asian countries[2,28]. GC has a poor prognosis in most patients due to late detection. Currently, the overall survival rate of EGC patients treated by endoscopy can exceed 90%[28,29]. Nonetheless, the 5-year survival rate of AGC patients with distant metastases is lower than 5%[30]. However, a screening program carried out by the Shanghai Research Institute in ten medical centers showed that the rate of EGC diagnosis is only 9.61%[28].

The clinical symptoms of EGC are atypical in most patients, and these symptoms include anorexia, malnutrition, and stomachache[2]. The methods of early diagnosis of GC include detection of standard serum biomarkers, barium radiography, computerized tomography, and endoscopic biopsy[31]. Over time, the role of liquid biopsy in GC has received close attention. Furthermore, liquid biopsy has emerged as a revolutionary strategy for the early diagnosis of cancers, detection of therapeutic targets, prediction of prognosis, monitoring of therapeutic efficacy, and analysis of drug resistance; it also has the advantage of being minimally invasive[14,32-34]. Although numerous studies have investigated biomarkers for the early detection of GC, there are still many limitations regarding the use of these biomarkers for the early diagnosis of GC. For example, CEA and CA72-4 are standard clinical biomarkers, but both lack sensitivity and specificity.

In recent years, exosomes have been found in nearly all types of human body fluids, such as blood, urine, breast milk, saliva, ascites, and cerebrospinal fluid. Because of their phospholipid bilayer membrane structure, they can protect bioactive cargos from degradation. There are many metabolites and products in exosomes produced by all kinds of cells. These cargoes include nucleic acids, proteins, lipids, and metabolites[35].

CircRNAs are a class of single-stranded noncoding RNAs[36]. Initially, circRNAs were considered to be the result of splicing errors. However, with the development of bioinformatics and high-throughput sequencing technologies, more circRNAs have been identified, and they have been found to be involved in the occurrence and development of many human diseases. Many studies have demonstrated that circRNAs are abundant, stable and conserved rather than random products of RNA splicing[36]. Due to their high stability, circRNAs have many important biological functions, including noncoding and coding functions. The most widely studied function is their role in the regulation of miRNA target genes as miRNA sponges or decoys. They can protect target mRNAs from miRNA-dependent degradation. Moreover, it has been found that circRNAs may function as protein sponges or decoys, enhancers of protein function, protein scaffolds, protein recruiters, and templates for translation[17,37].

For instance, Zhang *et al*[38] reported that exosomal circNRIP1, as a tumor promoter, sponges miR-149-5p to regulate the expression level of AKT1 in GC. Similarly, exosomal circSHKBP1 may be a promising circulating biomarker for GC diagnosis and prognosis[39]. Exosomal circSHKBP1 regulates the miR-582-3p/HUR/vascular endothelial growth factor pathway and suppresses HSP90 degradation to promote GC progression[39]. In addition, Lu *et al*[40] found that exosomal circ-RanGAP1 facilitates GC invasion and metastasis by targeting miR-877-3p to regulate vascular endothelial growth factor-A expression, suggesting that circ-RanGAP1 may act as a tumor promoter in GC.

In this study, we performed cluster analysis of exosomal circRNAs, lncRNAs, miRNAs, and mRNAs based on the results of whole-transcriptome RNA sequencing. The results showed that circRNAs could be used to distinguish GC patients from HDs better than lncRNAs, miRNAs, and mRNAs. Then, we investigated the expression of exosomal hsa\_circ\_0079439 in HDs and GC patients, including EGC and AGC, by dd-PCR. The expression levels of exosomal hsa\_circ\_0079439 were significantly higher in GC patients.

In recent years, dd-PCR has become the latest technology used for DNA quantification. The reaction volume containing the nucleic acids is divided into thousands of nanosized droplets, each of which either contains the gene of interest or does not. After PCR amplification, each droplet is detected one by one. A droplet with a fluorescence signal is interpreted as a 1, and a droplet without a fluorescence signal is interpreted as a 0. According to the Poisson distribution principle and the number and proportion of positive droplets, the initial copy number or concentration of the gene of interest can be obtained. There is no suitable reference gene in exosomes for normalization of the expression levels of circRNAs in real-time PCR (RT-PCR) experiments. Previous studies have shown that dd-PCR can be used to accurately quantify the copy numbers of specific nucleotides in plasma without external calibrators and has higher sensitivity than RT-PCR[41-44]. Therefore, we compared the diagnostic efficiency of exosomal hsa\_circ\_0079439 in GC patients, especially EGC patients, with standard clinical biomarkers, by dd-PCR. We found that exosomal hsa\_circ\_0079439 had higher sensitivity and specificity than standard clinical biomarkers. The findings of this study support the notion that plasma exosomal circRNAs could serve as biomarkers for the diagnosis of EGC and might be new therapeutic targets as well as effective prognostic markers for GC.

However, there are still some limitations to our study. First, the main limitation of this study is that since it was conducted at a single center, selection bias may have affected the results. This may indicate that this method is suitable for the early diagnosis of GC in Asians but not necessarily in other populations. Second, some groups had relatively few samples, so the generalizability of our study results may be affected. Third, since there is no standard isolation method for exosomes, the use of different isolation methods may result in differences in detection efficiency for the early diagnosis of GC[45-47]. Fourth, although circulating exosomal circRNAs serve as good candidates for blood-based biomarkers, it will take some time before they can be applied in the clinic. Therefore, multicenter studies with larger sample sizes are encouraged to obtain more accurate results for the early diagnosis of GC.

**CONCLUSION**

Based on whole-transcriptome RNA resequencing data, we found that circRNAs have greater potential than other RNA types as novel biomarkers for the detection of GC, especially EGC. To our knowledge, this study is the first to discover and verify that the levels of exosomal hsa\_circ\_0079439 are higher in GC patients than in HDs. In addition, exosomal hsa\_circ\_0079439 performs better in distinguishing EGC patients from HDs than standard clinical biomarkers. Overall, exosomal hsa\_circ\_0079439 is a prospective biomarker for the diagnosis of GC, including EGC and AGC.

**ARTICLE HIGHLIGHTS**

***Research background***

Gastric cancer (GC) is a major health problem worldwide, especially in East Asian countries, and GC has a poor prognosis in most patients due to late detection. Therefore, accurate early detection of GC is one of the most urgent issues in its management.

***Research motivation***

A number of studies have demonstrated that circular RNAs (circRNAs) play an important role in GC progression, invasion, and metastasis. However, the utility of exosomal circRNAs for early detection of GC is largely unknown.

***Research objectives***

To analyze the expression levels of plasma exosomal circRNAs from GC patients in different clinical stages to identify a novel biomarker for early detection of GC.

***Research methods***

Healthy donors (HDs) and GC patients diagnosed by pathology were recruited. Based on the results of whole-transcriptome RNA sequencing, the expression profiles of circRNAs were analyzed by bioinformatics methods and validated by droplet digital polymerase chain reaction. Then we compared the diagnostic efficiency of plasma exosomal circRNAs and standard serum biomarkers.

***Research results***

The expression levels of exosomal hsa\_circ\_0079439 were obviously higher in GC patients than in HDs (*P* < 0.0001). And the area under the curve value of exosomal hsa\_circ\_0079439 was obviously higher than those of carcinoembryonic antigen, carbohydrate antigen (CA)19-9, CA72-4, alpha-fetoprotein, and CA125 (0.8433 *vs* 0.5732, 0.5362, 0.5203, 0.5024, and 0.5352, respectively).

***Research conclusions***

Plasma exosomal hsa\_circ\_0079439 is a prospective biomarker for the diagnosis of GC.

***Research perspectives***

Multicenter studies with larger sample sizes are encouraged to obtain more accurate results for the early diagnosis of GC.

**REFERENCES**

1 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

2 **Smyth EC**, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. *Lancet* 2020; **396**: 635-648 [PMID: 32861308 DOI: 10.1016/S0140-6736(20)31288-5]

3 **Shimada H**, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. *Gastric Cancer* 2014; **17**: 26-33 [PMID: 23572188 DOI: 10.1007/s10120-013-0259-5]

4 **Feng F**, Tian Y, Xu G, Liu Z, Liu S, Zheng G, Guo M, Lian X, Fan D, Zhang H. Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer. *BMC Cancer* 2017; **17**: 737 [PMID: 29121872 DOI: 10.1186/s12885-017-3738-y]

5 **Liu X**, Cheng Y, Sheng W, Lu H, Xu Y, Long Z, Zhu H, Wang Y. Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. *J Surg Oncol* 2010; **102**: 249-255 [PMID: 20740583 DOI: 10.1002/jso.21624]

6 **Guo X**, Lv X, Ru Y, Zhou F, Wang N, Xi H, Zhang K, Li J, Chang R, Xie T, Wang X, Li B, Chen Y, Yang Y, Chen L, Chen L. Circulating Exosomal Gastric Cancer-Associated Long Noncoding RNA1 as a Biomarker for Early Detection and Monitoring Progression of Gastric Cancer: A Multiphase Study. *JAMA Surg* 2020; **155**: 572-579 [PMID: 32520332 DOI: 10.1001/jamasurg.2020.1133]

7 **Xu Y**, Zhang P, Zhang K, Huang C. The application of CA72-4 in the diagnosis, prognosis, and treatment of gastric cancer. *Biochim Biophys Acta Rev Cancer* 2021; **1876**: 188634 [PMID: 34656687 DOI: 10.1016/j.bbcan.2021.188634]

8 **Thanh Huong P**, Gurshaney S, Thanh Binh N, Gia Pham A, Hoang Nguyen H, Thanh Nguyen X, Pham-The H, Tran PT, Truong Vu K, Xuan Duong N, Pelucchi C, La Vecchia C, Boffetta P, Nguyen HD, Luu HN. Emerging Role of Circulating Tumor Cells in Gastric Cancer. *Cancers (Basel)* 2020; **12** [PMID: 32183503 DOI: 10.3390/cancers12030695]

9 **Zhou R**, Chen KK, Zhang J, Xiao B, Huang Z, Ju C, Sun J, Zhang F, Lv XB, Huang G. The decade of exosomal long RNA species: an emerging cancer antagonist. *Mol Cancer* 2018; **17**: 75 [PMID: 29558960 DOI: 10.1186/s12943-018-0823-z]

10 **Kok VC**, Yu CC. Cancer-Derived Exosomes: Their Role in Cancer Biology and Biomarker Development. *Int J Nanomedicine* 2020; **15**: 8019-8036 [PMID: 33116515 DOI: 10.2147/IJN.S272378]

11 **Hannafon BN**, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ. Plasma exosome microRNAs are indicative of breast cancer. *Breast Cancer Res* 2016; **18**: 90 [PMID: 27608715 DOI: 10.1186/s13058-016-0753-x]

12 **Xu H**, Zhou J, Tang J, Min X, Yi T, Zhao J, Ren Y. Identification of serum exosomal lncRNA MIAT as a novel diagnostic and prognostic biomarker for gastric cancer. *J Clin Lab Anal* 2020; **34**: e23323 [PMID: 32274858 DOI: 10.1002/jcla.23323]

13 **Kim KU**, Kim WH, Jeong CH, Yi DY, Min H. More than Nutrition: Therapeutic Potential of Breast Milk-Derived Exosomes in Cancer. *Int J Mol Sci* 2020; **21** [PMID: 33023062 DOI: 10.3390/ijms21197327]

14 **Yu D**, Li Y, Wang M, Gu J, Xu W, Cai H, Fang X, Zhang X. Exosomes as a new frontier of cancer liquid biopsy. *Mol Cancer* 2022; **21**: 56 [PMID: 35180868 DOI: 10.1186/s12943-022-01509-9]

15 **Memczak S**, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, Loewer A, Ziebold U, Landthaler M, Kocks C, le Noble F, Rajewsky N. Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 2013; **495**: 333-338 [PMID: 23446348 DOI: 10.1038/nature11928]

16 **Shan C**, Zhang Y, Hao X, Gao J, Chen X, Wang K. Biogenesis, functions and clinical significance of circRNAs in gastric cancer. *Mol Cancer* 2019; **18**: 136 [PMID: 31519189 DOI: 10.1186/s12943-019-1069-0]

17 **Kristensen LS**, Andersen MS, Stagsted LVW, Ebbesen KK, Hansen TB, Kjems J. The biogenesis, biology and characterization of circular RNAs. *Nat Rev Genet* 2019; **20**: 675-691 [PMID: 31395983 DOI: 10.1038/s41576-019-0158-7]

18 **Yu W**, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, Breakefield XO, Skog JK. Exosome-based liquid biopsies in cancer: opportunities and challenges. *Ann Oncol* 2021; **32**: 466-477 [PMID: 33548389 DOI: 10.1016/j.annonc.2021.01.074]

19 **Baassiri A**, Nassar F, Mukherji D, Shamseddine A, Nasr R, Temraz S. Exosomal Non Coding RNA in LIQUID Biopsies as a Promising Biomarker for Colorectal Cancer. *Int J Mol Sci* 2020; **21** [PMID: 32092975 DOI: 10.3390/ijms21041398]

20 **Poulet C**, Njock MS, Moermans C, Louis E, Louis R, Malaise M, Guiot J. Exosomal Long Non-Coding RNAs in Lung Diseases. *Int J Mol Sci* 2020; **21** [PMID: 32438606 DOI: 10.3390/ijms21103580]

21 **Yu J**, Huang C, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Hu Y, Liu H, Zheng C, Li P, Xie J, Liu F, Li Z, Zhao G, Yang K, Liu C, Li H, Chen P, Ji J, Li G; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Effect of Laparoscopic *vs* Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. *JAMA* 2019; **321**: 1983-1992 [PMID: 31135850 DOI: 10.1001/jama.2019.5359]

22 **Marano L**, D'Ignazio A, Cammillini F, Angotti R, Messina M, Marrelli D, Roviello F. Comparison between 7th and 8th edition of AJCC TNM staging system for gastric cancer: old problems and new perspectives. *Transl Gastroenterol Hepatol* 2019; **4**: 22 [PMID: 31143843 DOI: 10.21037/tgh.2019.03.09]

23 **He X**, Wu W, Lin Z, Ding Y, Si J, Sun LM. Validation of the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer patients: a population-based analysis. *Gastric Cancer* 2018; **21**: 391-400 [PMID: 29052053 DOI: 10.1007/s10120-017-0770-1]

24 **Digklia A**, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. *World J Gastroenterol* 2016; **22**: 2403-2414 [PMID: 26937129 DOI: 10.3748/wjg.v22.i8.2403]

25 **Böing AN**, van der Pol E, Grootemaat AE, Coumans FA, Sturk A, Nieuwland R. Single-step isolation of extracellular vesicles by size-exclusion chromatography. *J Extracell Vesicles* 2014; **3** [PMID: 25279113 DOI: 10.3402/jev.v3.23430]

26 **Pegtel DM**, Gould SJ. Exosomes. *Annu Rev Biochem* 2019; **88**: 487-514 [PMID: 31220978 DOI: 10.1146/annurev-biochem-013118-111902]

27 **Li W**, Gao YQ. MiR-217 is involved in the carcinogenesis of gastric cancer by down-regulating CDH1 expression. *Kaohsiung J Med Sci* 2018; **34**: 377-384 [PMID: 30063010 DOI: 10.1016/j.kjms.2018.02.003]

28 **Hu Y**, Fang JY, Xiao SD. Can the incidence of gastric cancer be reduced in the new century? *J Dig Dis* 2013; **14**: 11-15 [PMID: 23134264 DOI: 10.1111/j.1751-2980.2012.00647.x]

29 **Hatta W**, Gotoda T, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, Hoteya S, Nakagawa M, Hirano M, Esaki M, Matsuda M, Ohnita K, Yamanouchi K, Yoshida M, Dohi O, Takada J, Tanaka K, Yamada S, Tsuji T, Ito H, Hayashi Y, Nakaya N, Nakamura T, Shimosegawa T. A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: "eCura system". *Am J Gastroenterol* 2017; **112**: 874-881 [PMID: 28397873 DOI: 10.1038/ajg.2017.95]

30 **Mattiuzzi C**, Lippi G. Current Cancer Epidemiology. *J Epidemiol Glob Health* 2019; **9**: 217-222 [PMID: 31854162 DOI: 10.2991/jegh.k.191008.001]

31 **Karimi P**, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. *Cancer Epidemiol Biomarkers Prev* 2014; **23**: 700-713 [PMID: 24618998 DOI: 10.1158/1055-9965.EPI-13-1057]

32 **Vaidyanathan R**, Soon RH, Zhang P, Jiang K, Lim CT. Cancer diagnosis: from tumor to liquid biopsy and beyond. *Lab Chip* 2018; **19**: 11-34 [PMID: 30480287 DOI: 10.1039/c8lc00684a]

33 **Ignatiadis M**, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. *Nat Rev Clin Oncol* 2021; **18**: 297-312 [PMID: 33473219 DOI: 10.1038/s41571-020-00457-x]

34 **Alix-Panabières C**, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. *Cancer Discov* 2021; **11**: 858-873 [PMID: 33811121 DOI: 10.1158/2159-8290.CD-20-1311]

35 **Dai J**, Su Y, Zhong S, Cong L, Liu B, Yang J, Tao Y, He Z, Chen C, Jiang Y. Exosomes: key players in cancer and potential therapeutic strategy. *Signal Transduct Target Ther* 2020; **5**: 145 [PMID: 32759948 DOI: 10.1038/s41392-020-00261-0]

36 **Chen L**, Shan G. CircRNA in cancer: Fundamental mechanism and clinical potential. *Cancer Lett* 2021; **505**: 49-57 [PMID: 33609610 DOI: 10.1016/j.canlet.2021.02.004]

37 **Li R**, Jiang J, Shi H, Qian H, Zhang X, Xu W. CircRNA: a rising star in gastric cancer. *Cell Mol Life Sci* 2020; **77**: 1661-1680 [PMID: 31659415 DOI: 10.1007/s00018-019-03345-5]

38 **Zhang X**, Wang S, Wang H, Cao J, Huang X, Chen Z, Xu P, Sun G, Xu J, Lv J, Xu Z. Circular RNA circNRIP1 acts as a microRNA-149-5p sponge to promote gastric cancer progression *via* the AKT1/mTOR pathway. *Mol Cancer* 2019; **18**: 20 [PMID: 30717751 DOI: 10.1186/s12943-018-0935-5]

39 **Xie M**, Yu T, Jing X, Ma L, Fan Y, Yang F, Ma P, Jiang H, Wu X, Shu Y, Xu T. Exosomal circSHKBP1 promotes gastric cancer progression *via* regulating the miR-582-3p/HUR/VEGF axis and suppressing HSP90 degradation. *Mol Cancer* 2020; **19**: 112 [PMID: 32600329 DOI: 10.1186/s12943-020-01208-3]

40 **Lu J**, Wang YH, Yoon C, Huang XY, Xu Y, Xie JW, Wang JB, Lin JX, Chen QY, Cao LL, Zheng CH, Li P, Huang CM. Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis. *Cancer Lett* 2020; **471**: 38-48 [PMID: 31811909 DOI: 10.1016/j.canlet.2019.11.038]

41 **Pinheiro LB**, Coleman VA, Hindson CM, Herrmann J, Hindson BJ, Bhat S, Emslie KR. Evaluation of a droplet digital polymerase chain reaction format for DNA copy number quantification. *Anal Chem* 2012; **84**: 1003-1011 [PMID: 22122760 DOI: 10.1021/ac202578x]

42 **Li T**, Shao Y, Fu L, Xie Y, Zhu L, Sun W, Yu R, Xiao B, Guo J. Plasma circular RNA profiling of patients with gastric cancer and their droplet digital RT-PCR detection. *J Mol Med (Berl)* 2018; **96**: 85-96 [PMID: 29098316 DOI: 10.1007/s00109-017-1600-y]

43 **Sillence KA**, Roberts LA, Hollands HJ, Thompson HP, Kiernan M, Madgett TE, Welch CR, Avent ND. Fetal Sex and RHD Genotyping with Digital PCR Demonstrates Greater Sensitivity than Real-time PCR. *Clin Chem* 2015; **61**: 1399-1407 [PMID: 26354802 DOI: 10.1373/clinchem.2015.239137]

44 **Huggett JF**, Cowen S, Foy CA. Considerations for digital PCR as an accurate molecular diagnostic tool. *Clin Chem* 2015; **61**: 79-88 [PMID: 25338683 DOI: 10.1373/clinchem.2014.221366]

45 **Nordin JZ**, Lee Y, Vader P, Mäger I, Johansson HJ, Heusermann W, Wiklander OP, Hällbrink M, Seow Y, Bultema JJ, Gilthorpe J, Davies T, Fairchild PJ, Gabrielsson S, Meisner-Kober NC, Lehtiö J, Smith CI, Wood MJ, El Andaloussi S. Ultrafiltration with size-exclusion liquid chromatography for high yield isolation of extracellular vesicles preserving intact biophysical and functional properties. *Nanomedicine* 2015; **11**: 879-883 [PMID: 25659648 DOI: 10.1016/j.nano.2015.01.003]

46 **Van Deun J**, Mestdagh P, Sormunen R, Cocquyt V, Vermaelen K, Vandesompele J, Bracke M, De Wever O, Hendrix A. The impact of disparate isolation methods for extracellular vesicles on downstream RNA profiling. *J Extracell Vesicles* 2014; **3** [PMID: 25317274 DOI: 10.3402/jev.v3.24858]

47 **Tang XH**, Guo T, Gao XY, Wu XL, Xing XF, Ji JF, Li ZY. Exosome-derived noncoding RNAs in gastric cancer: functions and clinical applications. *Mol Cancer* 2021; **20**: 99 [PMID: 34330299 DOI: 10.1186/s12943-021-01396-6]

**Footnotes**

**Institutional review board statement:** This study was approved by the ethics committee of Chinese PLA General Hospital.

**Informed consent statement:** Informed consent was obtained from all participants in this study.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** The data that support the findings of this study are available from the corresponding author upon reasonable request.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author’s Membership in Professional Societies:** Chinese Society of Digestive Endoscopy, President; Endoscopy Branch of Chinese Medical Association, Vice President; Digestive Endoscopy Branch, Beijing Medical Association, President; Digestive Endoscopy Branch, Beijing Physicians Association, President; Chinese Journal of Gastroenteroscopy Electronics, Editor-in-chief; Chinese Journal of Digestive Endoscopy, Vice President.

**Peer-review started:** April 16, 2023

**First decision:** April 28, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0


**P-Reviewer:** Liu L, China; Schmidt T, Germany **S-Editor:** Wang JJ **L-Editor:** Wang TQ **P-Editor:**


**Figure Legends**





**Figure 1** **Study design.** HD: Healthy donor; GC: Gastric cancer; EGC: Early gastric cancer; LAGC: Locally advanced gastric cancer; MGC: Metastatic gastric cancer; circRNA: Circular RNA; AGC: Advanced gastric cancer.

















**Figure 2** **Identification of exosomes and bioinformatic analysis of exosomal circular RNAs.** A: Exosomes were observed by transmission electron microscopy. The scale bar is 200 nm; B: Diameter and quantity of the exosomes; C: The positive markers of exosomes (CD9, TSG101, and CD81) and the negative marker (Calnexin) were tested by Western blot; D: Clustering analysis of circular RNAs (circRNAs); E: Kyoto Encyclopedia of Genes and Genomes pathway analysis of cluster 5 of differently expressed circRNAs; F: Gene Ontology enrichment analysis of cluster 5 of differently expressed circRNAs. HD: Healthy donor; GC: Gastric cancer; EGC: Early gastric cancer; LAGC: Locally advanced gastric cancer; MGC: Metastatic gastric cancer; AGC: Advanced gastric cancer; BP: Biological process; CC: Cell component; MF: Molecular function.




**Figure 3 Expression levels of exosomal hsa\_circ\_0079439,** **carcinoembryonic antigen, carbohydrate antigen 19-9,** **carbohydrate antigen 72-4,** **alpha-fetoprotein, and** **carbohydrate antigen 125 in the test cohort.** A: Absolutely quantitative detection of exosomal hsa\_circ\_0079439 copy number in plasma between healthy donors (HDs) (*n* = 22) and gastric cancer (GC) patients (*n* = 69) by droplet digital polymerase chain reaction; B-F: Expression levels of standard serum biomarkers in HDs and GC patients, including carcinoembryonic antigen (B), carbohydrate antigen (CA)19-9 (C), CA72-4 (D), alpha-fetoprotein (E), and CA125 (F). And all the results are shown as the mean (SD). a*P* < 0.001, b*P* < 0.0001, ns: Not significant. HD: Healthy donor; GC: Gastric cancer; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4; CA 125: Carbohydrate antigen 125; AFP: Alpha-fetoprotein.





**Figure 4 Expression levels of exosomal hsa\_circ\_0079439, carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4, alpha-fetoprotein, and carbohydrate antigen 125 in the validation cohort.** A: Absolutely quantitative detection of exosomal hsa\_circ\_0079439 copy number in plasma from healthy donors (HDs) (*n* = 41) and gastric cancer (GC) patients (*n* = 171) by droplet digital polymerase chain reaction; B-F: Expression levels of standard serum biomarkers in GC patients and HDs, including carcinoembryonic antigen (B), carbohydrate antigen (CA)19-9 (C), CA72-4 (D), alpha-fetoprotein (E), and CA125 (F). And all the results are shown as mean (SD). a*P* < 0.0001, ns: Not significant. HD: Healthy donor; GC: Gastric cancer; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4; CA 125: Carbohydrate antigen 125; AFP: Alpha-fetoprotein.





**Figure 5** **Diagnostic value and expression levels of exosomal hsa\_circ\_0079439, carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4, alpha-fetoprotein, and carbohydrate antigen 125 in total participants for gastric cancer.** A: Absolutely quantitative detection of exosomal hsa\_circ\_0079439 copy number in plasma from healthy donors (HDs) (*n* = 63) and gastric cancer (GC) patients (*n* = 240) by droplet digital polymerase chain reaction; B-F: Expression levels of standard serum biomarkers in GC patients and HDs, including carcinoembryonic antigen (B), carbohydrate antigen (CA)19-9 (C), CA72-4 (D), alpha-fetoprotein (E), and CA125 (F); G: Receiver operating characteristic curves of hsa\_circ\_0079439, carcinoembryonic antigen, CA19-9, CA72-4, alpha-fetoprotein, and CA125 in distinguish GC patients (*n* = 240) from HDs (*n* = 63); H: Changes of expression levels of exosomal hsa\_circ\_0079439 before and after treatment. And all the results are shown as the mean (SD). a*P* < 0.05, b*P* < 0.0001, ns: Not significant. HD: Healthy donor; GC: Gastric cancer; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4; CA 125: Carbohydrate antigen 125; AFP: Alpha-fetoprotein.





**Figure 6** **Diagnostic value and expression levels of exosomal hsa\_circ\_0079439, carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4, alpha-fetoprotein, and carbohydrate antigen 125 among healthy donors, early gastric cancer patients, and advanced gastric cancer patients.** A: Absolutely quantitative detection of exosomal hsa\_circ\_0079439 copy number in plasma from early gastric cancer (EGC) patients (*n* = 177), advanced GC (AGC) patients (*n* = 63), and healthy donors (HDs) (*n* = 63) by droplet digital polymerase chain reaction; B-F: Expression levels of standard serum biomarkers in EGC patients, AGC patients, and HDs, including carcinoembryonic antigen (CEA) (B), carbohydrate antigen (CA)19-9 (C), CA72-4 (D), alpha-fetoprotein (E), and CA125 (F); G: Receiver operating characteristic (ROC) curves of hsa\_circ\_0079439, CEA, CA19-9, CA72-4, alpha-fetoprotein, and CA125 in distinguish EGC patients from HDs; H: ROC curves of hsa\_circ\_0079439, CEA, CA19-9, CA72-4, alpha-fetoprotein, and CA125 in distinguish AGC patients from HDs. All the results are shown as the mean (SD). a*P* < 0.05, b*P* < 0.0001, ns: Not significant. HD: Healthy donor; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9; CA72-4: Carbohydrate antigen 72-4; CA 125: Carbohydrate antigen 125; AFP: Alpha-fetoprotein; EGC: Early gastric cancer; AGC: Advanced gastric cancer.

**Table 1** **Clinical characteristics of individuals in test cohort and validation cohort, and total participants, *n* (%)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristic** | **Test cohort (*n* = 91)** | | **Validation cohort (*n* = 212)** | | **Total participants (*n* = 303)** | |
| **HD (*n* = 22)** | **GC (*n* = 69)** | **HD (*n* = 41)** | **GC (*n* = 171)** | **HD (*n* = 63)** | **GC (*n* = 240)** |
| Gender |  |  |  |  |  |  |
| Male | 12 (54.55) | 51 (73.91) | 31 (75.61) | 136 (79.53) | 43 (68.25) | 187 (77.92) |
| Female | 10 (45.45) | 18 (26.09) | 10 (24.39) | 35 (20.47) | 20 (31.75) | 53 (22.08) |
| Age (yr), median (range) | 54 (32-77) | 66 (35-84) | 53 (24-81) | 64 (34-94) | 53 (24-81) | 64 (34-94) |
| T stage | / |  | / |  | / |  |
| T1 |  | 69 (100.00) |  | 108 (63.16) |  | 177 (73.75) |
| T2 |  | 0 |  | 7 (4.09) |  | 7 (2.92) |
| T3 |  | 0 |  | 37 (21.64) |  | 37 (15.42) |
| T4 |  | 0 |  | 19 (11.11) |  | 19 (7.91) |
| N stage | / |  | / |  | / |  |
| N0 |  | 69 (100.00) |  | 124 (72.51) |  | 193 (80.42) |
| N1 |  | 0 |  | 11 (6.43) |  | 11 (4.58) |
| N2 |  | 0 |  | 14 (8.19) |  | 14 (5.83) |
| N3 |  | 0 |  | 22 (12.87) |  | 22 (9.17) |
| M stage | / |  | / |  | / |  |
| M0 |  | 69 (100.00) |  | 162 (94.74) |  | 231 (96.25) |
| M1 |  | 0 |  | 9 (5.26) |  | 9 (3.75) |
| Clinical stage | / |  | / |  | / |  |
| I |  | 69 (100.00) |  | 111 (64.91) |  | 180 (75.00) |
| II |  | 0 |  | 16 (9.36) |  | 16 (6.67) |
| III |  | 0 |  | 35 (20.47) |  | 35 (14.58) |
| IV |  | 0 |  | 9 (5.26) |  | 9 (3.75) |

HD: Healthy donor; GC: Gastric cancer.